193 related articles for article (PubMed ID: 10699345)
1. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
[TBL] [Abstract][Full Text] [Related]
2. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
[TBL] [Abstract][Full Text] [Related]
3. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
[TBL] [Abstract][Full Text] [Related]
4. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.
Belyakov IM; Ahlers JD; Clements JD; Strober W; Berzofsky JA
J Immunol; 2000 Dec; 165(11):6454-62. PubMed ID: 11086085
[TBL] [Abstract][Full Text] [Related]
5. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
[TBL] [Abstract][Full Text] [Related]
6. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
[TBL] [Abstract][Full Text] [Related]
7. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
8. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis.
Cárdenas-Freytag L; Cheng E; Mayeux P; Domer JE; Clements JD
Infect Immun; 1999 Feb; 67(2):826-33. PubMed ID: 9916097
[TBL] [Abstract][Full Text] [Related]
10. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
Tumpey TM; Renshaw M; Clements JD; Katz JM
J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
[TBL] [Abstract][Full Text] [Related]
11. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
Lu X; Clements JD; Katz JM
Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
[TBL] [Abstract][Full Text] [Related]
13. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
Vinner L; Nielsen HV; Bryder K; Corbet S; Nielsen C; Fomsgaard A
Vaccine; 1999 Apr; 17(17):2166-75. PubMed ID: 10367950
[TBL] [Abstract][Full Text] [Related]
14. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
[TBL] [Abstract][Full Text] [Related]
16. Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines.
Smith DJ; King WF; Barnes LA; Trantolo D; Wise DL; Taubman MA
Infect Immun; 2001 Aug; 69(8):4767-73. PubMed ID: 11447149
[TBL] [Abstract][Full Text] [Related]
17. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
[TBL] [Abstract][Full Text] [Related]
18. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
[TBL] [Abstract][Full Text] [Related]
20. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants.
Lemere CA; Spooner ET; Leverone JF; Mori C; Clements JD
Neurobiol Aging; 2002; 23(6):991-1000. PubMed ID: 12470794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
